XOMA - XOMA Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.45
-0.08 (-0.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close18.53
Open18.43
Bid13.99 x 900
Ask27.00 x 800
Day's Range18.06 - 18.90
52 Week Range11.58 - 28.85
Volume26,198
Avg. Volume60,752
Market Cap180.107M
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)-0.23
Earnings DateMar 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.33
  • Can You Imagine How Chuffed XOMA's (NASDAQ:XOMA) Shareholders Feel About Its 215% Share Price Gain?
    Simply Wall St.

    Can You Imagine How Chuffed XOMA's (NASDAQ:XOMA) Shareholders Feel About Its 215% Share Price Gain?

    It certainly might concern XOMA Corporation (NASDAQ:XOMA) shareholders to see the share price down 33% in just 30...

  • GlobeNewswire

    XOMA Reports Fourth Quarter and Full-Year 2019 Financial Results and Operating Highlights

    Added more than 20 new partner-funded programs in 2019 with potential for milestone and royalty payments Received $15.8 million from partners during the year Current cash.

  • GlobeNewswire

    Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement

    Zydus Cadila, an innovation-driven global pharmaceutical company, and XOMA Corporation (XOMA) today announced they have entered into a licensing agreement to advance an IL-2-based immuno-oncology (IO) drug candidate that combines Zydus’ IL-2 with XOMA’s novel anti-IL-2 monoclonal antibody. As part of the agreement, Zydus will advance the new IO candidate through formal clinical trials. Zydus has been granted exclusive rights to develop and commercialize the therapy in India, Brazil, Mexico and other emerging markets, and XOMA has the potential to receive single-to double-digit royalties on commercial sales in those territories.

  • Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
    Zacks

    Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

    Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    XOMA to Present at the Cowen and Company 40th Annual Health Care Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the Company’s business at the Cowen and Company 40th Annual Health Care Conference in Boston, Massachusetts. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings.

  • Before You Buy XOMA Corporation (NASDAQ:XOMA), Consider Its Volatility
    Simply Wall St.

    Before You Buy XOMA Corporation (NASDAQ:XOMA), Consider Its Volatility

    If you own shares in XOMA Corporation (NASDAQ:XOMA) then it's worth thinking about how it contributes to the...

  • Will XOMA Continue to Surge Higher?
    Zacks

    Will XOMA Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in XOMA.

  • Should You Avoid XOMA Corp (XOMA)?
    Insider Monkey

    Should You Avoid XOMA Corp (XOMA)?

    The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]

  • GlobeNewswire

    XOMA Announces Closing of Rights Offering

    At the closing, XOMA sold and issued an aggregate of 626,805 shares of its common stock (the “Common Stock”) pursuant to the exercise of subscriptions in the Rights Offering from its existing stockholders. In addition, BVF Partners L.P., a stockholder of the Company, purchased an additional 373,195 shares of Common Stock pursuant to the exercise of its oversubscription rights. Combined, the Company sold and issued an aggregate of 1,000,000 shares of Common Stock for aggregate gross proceeds of $22 million.

  • 5 Biotech Stocks Set for Continued Rally in 2020
    Zacks

    5 Biotech Stocks Set for Continued Rally in 2020

    The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

  • GlobeNewswire

    Iscalimab (CFZ533) Update

    As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candidate, for which XOMA (XOMA) has the potential to earn royalties that are tiered from a mid-single to a low teens percentage rate based on sales levels, if this investigational compound is approved and commercialized. Novartis dedicated eight (8) slides to the iscalimab update. Please find the Novartis R&D Day Presentation on the Novartis website (slide numbers 1, 2, 64-71).

  • GlobeNewswire

    XOMA Announces Commencement of Rights Offering

    Under the terms of the Rights Offering, the holders of XOMA’s common stock and Series X Preferred Stock and Series Y Preferred Stock as of 5:00 p.m., New York time, on November 29, 2019, the record date for the Rights Offering, are entitled to purchase up to 1,000,000 shares of common stock in the aggregate at a subscription price equal to $22.00 per share, or under certain circumstances, shares of non-voting Series Z preferred stock in lieu of common stock (collectively, the “Offered Shares”), as more fully described in the prospectus supplement, dated December 2, 2019, relating to the Rights Offering.

  • GlobeNewswire

    XOMA Announces Proposed Rights Offering

    Rights Offering will be available to all shareholders of record on November 29, 2019$22 million to be raised; fully backstopped EMERYVILLE, Calif., Nov. 19, 2019 -- XOMA.

  • GlobeNewswire

    XOMA Reports Third Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results

    EMERYVILLE, Calif., Nov. 05, 2019 -- XOMA Corporation (Nasdaq: XOMA) today reported its third quarter 2019 financial results.  “XOMA’s portfolio of future potential royalty-.

  • Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know
    Zacks

    Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know

    Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • How Much Are XOMA Corporation (NASDAQ:XOMA) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are XOMA Corporation (NASDAQ:XOMA) Insiders Spending On Buying Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • Benzinga

    The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline ...

  • GlobeNewswire

    XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets

    XOMA Corporation (XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.  One of the assets, NIR178, is being developed by Novartis as a novel checkpoint inhibitor for the treatment of solid tumors.  Five of the assets are being developed by Palobiofarma.

  • GlobeNewswire

    XOMA to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will provide a corporate update at the 2019 Cantor Fitzgerald Global Healthcare Conference, taking place October 2-4, 2019, in New York, New York.  The presentation will take place on Wednesday, October 2, 2019 at 7:45AM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com.  An archived version of the webcast will be available for 90 days after the event. XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  For more information, visit www.xoma.com.

  • What Did XOMA Corporation's (NASDAQ:XOMA) CEO Take Home Last Year?
    Simply Wall St.

    What Did XOMA Corporation's (NASDAQ:XOMA) CEO Take Home Last Year?

    Jim Neal became the CEO of XOMA Corporation (NASDAQ:XOMA) in 2016. This report will, first, examine the CEO...

  • GlobeNewswire

    XOMA to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the H.C. Wainwright 21st Annual Global Investment Conference, in New York, New York.  The presentation will take place on Tuesday, September 10, 2019, at 10:00AM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com or by clicking http://wsw.com/webcast/hcw5/xoma/.  An archived version of the webcast will be available for 90 days after the event. EXPLANATORY NOTE: All references to “portfolio” in this press release are to milestone and/or royalty rights associated with drug products in development.  All references to “assets” in this presentation are to milestone and/or royalty rights associated with individual drug products in development.

  • Health Check: How Prudently Does XOMA (NASDAQ:XOMA) Use Debt?
    Simply Wall St.

    Health Check: How Prudently Does XOMA (NASDAQ:XOMA) Use Debt?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • GlobeNewswire

    XOMA’s Royalty Portfolio Expands Significantly

    XOMA Corporation (XOMA), today announced its portfolio of potential future royalty and milestone payments has significantly increased with the addition of Janssen Biotech, Inc. drug candidates for which XOMA could receive future milestone and royalty payments. In addition, Janssen has elected to accelerate its base annual license fee obligation and will make a one-time $2.5 million payment to XOMA. For each program, XOMA is entitled to receive milestone payments upon the achievement of certain clinical development and regulatory approval events.

  • Xoma (XOMA) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Xoma (XOMA) Reports Q2 Loss, Tops Revenue Estimates

    Xoma (XOMA) delivered earnings and revenue surprises of 14.55% and 52.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?